Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 9/20 | 1.00 |
| ▸ | LMNA | P02545 | 7/20 | 1.00 |
| ▸ | CTSV | O60911 | 5/20 | 1.00 |
| ▸ | CTSL | P07711 | 5/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 1.00 |
| ▸ | TP53 | P04637 | 2/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 1.00 |
| ▸ | TUBB4A | P04350 | 1/20 | 1.00 |
| ▸ | TUBB | P07437 | 1/20 | 1.00 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 1.00 |
| ▸ | TUBA1B | P68363 | 1/20 | 1.00 |
| ▸ | TUBA4A | P68366 | 1/20 | 1.00 |
| ▸ | TUBB4B | P68371 | 1/20 | 1.00 |
| ▸ | TUBB3 | Q13509 | 1/20 | 1.00 |
| ▸ | TUBB2A | Q13885 | 1/20 | 1.00 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 1.00 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 1.00 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 1.00 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29411863 | 1.00 | HPGD (1.00) | HPGDLMNACTSVCTSLKDM4E | |
| Acetic Acid SCHEMBL6142950 | 0.92 | HPGD (0.84) | HPGDLMNACTSVCTSLKDM4E | |
| SCHEMBL2630603 | 0.86 | HPGD (0.76) | HPGDLMNACTSVCTSLKDM4E | |
| SCHEMBL6001723 | 0.86 | CTSV (0.75) | HPGDLMNACTSVCTSLKDM4E | |
| SCHEMBL30935678 | 0.86 | HPGD (1.00) | HPGDLMNACTSVCTSLKDM4E | |
| SCHEMBL30462938 | 0.86 | KDM4E (1.00) | HPGDLMNACTSVCTSLKDM4E | |
| SCHEMBL311524 | 0.86 | CTSV (0.75) | HPGDLMNACTSVCTSLKDM4E | |
| SCHEMBL6001399 | 0.86 | CTSV (1.00) | HPGDLMNACTSVCTSLKDM4E | |
| SCHEMBL29411879 | 0.86 | CTSV (1.00) | HPGDLMNACTSVCTSLKDM4E | |
| SCHEMBL6534180 | 0.86 | HPGD (1.00) | HPGDLMNACTSVCTSLKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 184 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220273608-A1 | Methods for Treating Bone-Related Disorders | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2022-09-01 | — | — | US | claimed |
| US-20190351055-A1 | Methods for Treating Bone-Related Disorders | UNIVERSITY OF BALTIMORE, MARYLAND (US) | 2019-11-21 | — | — | US | claimed |
| EP-3541474-A1 | METHODS FOR TREATING BONE-RELATED DISORDERS | University Of Maryland, Baltimore (US) | 2019-09-25 | — | — | EP | claimed |
| CN-109516976-A | The crystal form and preparation method thereof of substituted uracil PI3K inhibitor mesylate | 南京圣和药业股份有限公司 | 2019-03-26 | — | — | CN | claimed |
| WO-2018094059-A1 | METHODS FOR TREATING BONE-RELATED DISORDERS | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2018-05-24 | — | — | WO | claimed |
| US-9511117-B2 | Treatment of muscular conditions and muscular dystrophies | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2016-12-06 | — | — | US | claimed |
| US-9029394-B2 | 2-phenyl-4-quinolones as anticancer agents | CHINA MEDICAL UNIVERSITY (TW) | 2015-05-12 | — | — | US | claimed |
| US-20140256644-A1 | Treatment of Muscular Conditions and Muscular Dystrophies | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-09-11 | — | — | US | claimed |
| EP-2455369-B1 | Derivatives of 2-aryl-4-quinolones having an aminoalkyl group as anticancer agents | UNIV CHINA MEDICAL (TW) | 2014-09-03 | — | — | EP | claimed |
| US-20130252999-A1 | 2-PHENYL-4-QUINOLONES AS ANTICANCER AGENTS | CHINA MEDICAL UNIVERSITY (TW) | 2013-09-26 | — | — | US | claimed |
| US-20100168064-A1 | NOVEL HYDROPHILIC DERIVATIVES OF 2-ARYL-4-QUINOLONES AS ANTICANCER AGENTS | CHINA MEDICAL UNIVERSITY (TW) | 2010-07-01 | — | — | US | claimed |
| CN-101583280-A | Novel hydrophilic derivatives of 2-aryl-4-quinolones as anticancer agents | UNIV CHINA MEDICAL (CN) | 2009-11-18 | — | — | CN | claimed |
| EP-2096924-A1 | NOVEL HYDROPHILIC DERIVATIVES OF 2-ARYL-4-QUINOLONES AS ANTICANCER AGENTS | China Medical University (TW) | 2009-09-09 | — | — | EP | claimed |
| WO-2008070176-A1 | NOVEL HYDROPHILIC DERIVATIVES OF 2-ARYL-4-QUINOLONES AS ANTICANCER AGENTS | CHINA MEDICAL UNIVERSITY (TW) | 2008-06-12 | — | — | WO | claimed |
| JP-2002522388-A | — | — | 2002-07-23 | — | — | JP | claimed |
| EP-1107759-A1 | PYRIDINONES FOR THE TREATMENT OF SEXUAL DYSFUNCTION | Basf Corporation (US) | 2001-06-20 | — | — | EP | claimed |
| WO-2000035865-A2 | TUBULIN-BINDING AGENTS | TULARIK INC. (US) | 2000-06-22 | — | — | WO | claimed |
| WO-2000007595-A1 | PYRIDINONES FOR THE TREATMENT OF SEXUAL DYSFUNCTION | BASF CORPORATION (US) | 2000-02-17 | — | — | WO | claimed |
| US-5571822-A | AMINO-2-PHENYL-4-QUINOLONE DERIVATIVES | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 1996-11-05 | — | — | US | claimed |
| WO-1996010563-A1 | 2-ARYL-4-QUINOLONES AS ANTITUMOR COMPOUNDS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 1996-04-11 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168064-A1 | NOVEL HYDROPHILIC DERIVATIVES OF 2-ARYL-4-QUINOLONES AS ANTICANCER AGENTS | DHX30, SLC20A2, DDX20 | HPGD 1886/4885LMNA 4383/4885CTSV 4217/4885 |
| US-20130252999-A1 | 2-PHENYL-4-QUINOLONES AS ANTICANCER AGENTS | PPIP5K2, DDX5, DHX30 | HPGD 2307/4885LMNA 4539/4885CTSV 4417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.